Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults

Post Date: 
Clinical Sites: 

Background: Many HIV-infected individuals present with advanced HIV disease. These patients are at high risk of death after antiretroviral therapy (ART) initiation, but risk factors for death in these patients are unclear.

Methods: We used data from a multisite randomized trial comparing empiric vs. preventive tuberculosis therapy in HIV-infected adults initiating ART with CD4 T-cell counts less than 50 cells/μl to evaluate risk factors for death within 48 weeks after ART initiation. Cox proportional hazards models were fit to evaluate characteristics present at baseline and at 4 weeks after ART initiation, including the week 4 CD4 T-cell response and new opportunistic infections.

Results: Of 850 enrolled, the median pre-ART CD4 T-cell count was 18 cells/μl and 67 (7.9%) died. Baseline risk factors for death included lymphadenopathy, lower CD4 T-cell count, lower serum albumin, high white blood cell count, elevated neutrophil percentage, and lower hemoglobin. Among 746 participants with data at week 4, the median changes in CD4 T-cell count and viral load for those who died (n = 43) vs. survived were 26 vs. 56 cells/μl and -2.7 vs. -2.7 log10 copies/ml, respectively. Each 20 cell/μl lower change in week 4 CD4 T-cell count was associated with a 20% increased risk of post week-4 mortality (adjusted hazard ratio 1.20, 1.01-1.42, P = .038).

Conclusion: Evidence of active infection and suboptimal immunologic response during the first month of ART are associated with death in the first year after ART initiation in those with advanced HIV disease taking tuberculosis preventive therapy. Strategies to reduce early mortality in this population warrant further investigation.

Bisson GP, Ramchandani R, Miyahara S, Mngqibisa R, Matoga M, Ngongondo M, Samaneka W, Koech L, Naidoo K, Rassool M, Kirui F, Banda P, Mave V, Kadam D, Leger P, Henestroza G, Manabe YC, Bao J, Kumwenda J, Gupta A, Hosseinipour MC; Adult AIDS Clinical Trials Group A5274 (REMEMBER) Study Team. Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults. AIDS. 2017 Oct 23;31(16):2217-2225. doi: 10.1097/QAD.0000000000001606.
  • Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
  • Harvard T.H. Chan School of Public Health, Boston, Massachusetts
  • Durban International CRS, Enhancing Care Foundation, Durban, South Africa
  • UNC Project, Lilongwe, Malawi
  • University of Zimbabwe, Harare, Zimbabwe
  • Kenya Medical Research Institute (KEMRI), Kericho, Kenya
  • South African MRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit
  • Clinical HIV Research Unit, Department of Medicine, University of Witwatersrand, Johannesburg, South Africa
  • Johns Hopkins Project, Blantyre
  • University of Malawi, College of Medicine, Blantyre, Malawi
  • GHESKIO, Port-au-Prince, Haiti
  • Center for Infectious Diseases Research, Lusaka, Zambia
  • HJF-DAIDS, Division of The Henry M. Jackson Foundation, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland
  • University of North Carolina School of Medicine, Chapel Hill, North Carolina